Adverse effects: Incidence of serious adverse effects · adults with schizophrenia
It is very uncertain whether ASENAPINE changes adverse effects: Incidence of serious adverse effects compared with PLACEBO (very low certainty).
1 finding from 1 review
Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks) vs. standard higher dose (> 7.5‐15 mg/day) · adults with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early · adults with schizophrenia
It is very uncertain whether ASENAPINE changes leaving the study early ‐ any reason compared with PLACEBO (very low certainty).
1 finding from 1 review
Costs · adults with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death · patients with schizophrenia
1 finding from 1 review
Relapse · patients with schizophrenia
It is very uncertain whether CHLORPROMAZINE changes relapse compared with PLACEBO (very low certainty).
1 finding from 1 review
Global state: no overall improvement (psychiatrist ‐ rated) · patients with schizophrenia
It is very uncertain whether CHLORPROMAZINE changes global state: no overall improvement (psychiatrist ‐ rated) compared with PLACEBO (very low certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
CHLORPROMAZINE may leads to lower leaving the study early compared with PLACEBO (low certainty).
1 finding from 1 review
Satisfaction with treatment ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Behaviour: deteriorated/ disturbed/un‐cooperative · patients with schizophrenia
It is very uncertain whether CHLORPROMAZINE changes behaviour: deteriorated/ disturbed/un‐cooperative compared with PLACEBO (very low certainty).
1 finding from 1 review
Cost of care ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death ‐ 2 years · patients with people with severe mental illnesses
It is very uncertain whether SHORT changes death ‐ 2 years compared with LONG HOSPITAL STAY (very low certainty).
1 finding from 1 review
No clinically important changes in specific symptoms ‐ positive and negative symptoms of schizophrenia (long term) Mental state: Not improved ‐ by 2 years ‐ as measured by PEF scale PEF scale · patients with people with severe mental illnesses
It is very uncertain whether SHORT changes no clinically important changes in specific symptoms ‐ positive and… compared with LONG HOSPITAL STAY (very low certainty).
1 finding from 1 review
Patient readmissions · patients with people with severe mental illnesses
SHORT showed no clear difference in service outcomes: 1a. Readmission to hospital (homogeneous studies)… compared with LONG HOSPITAL STAY (low certainty).
1 finding from 1 review
Service outcomes: 3. Leaving hospital prematurely ‐ by 2 years Participants leaving the study prematurely · patients with people with severe mental illnesses
SHORT showed no clear difference in service outcomes: 3. Leaving hospital prematurely ‐ by 2 years… compared with LONG HOSPITAL STAY (low certainty).
1 finding from 1 review
Service outcomes: 4. Discharge delayed beyond the time planned in study ‐ 2‐year data Number of participants kept beyond projected time of discharge · patients with people with severe mental illnesses
SHORT may leads to lower service outcomes: 4. Discharge delayed beyond the time planned in… compared with LONG HOSPITAL STAY (low certainty).
1 finding from 1 review
Leaving the study early · patients with people with severe mental illnesses
SHORT showed no clear difference in leaving the study early (long term) Participants leaving the study… compared with LONG HOSPITAL STAY (low certainty).
1 finding from 1 review
General functioning: Unemployed, unable to housekeep or unknown employment status ‐ by 2 years Number of participants with poor occupational functioning in 2 years · patients with people with severe mental illnesses
It is very uncertain whether SHORT changes general functioning: Unemployed, unable to housekeep or unknown… compared with LONG HOSPITAL STAY (very low certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
It is very uncertain whether adjunctive carbamazepine + antipsychotics changes acceptability of treatment Leaving the study early due to any reason compared with placebo/no adjunctive treatment + antipsychotics (very low certainty).
1 finding from 1 review
Mental state: No clinically important improvement · patients with schizophrenia
Adjunctive carbamazepine + antipsychotics showed no clear difference in no clinically important change in general mental state Scale used:… compared with placebo/no adjunctive treatment + antipsychotics (low certainty).
1 finding from 1 review